The report highlights the company's commitment to glycoscience research and development, focusing on its key areas of specialization, including orthopedic disorders and ophthalmic diseases. It also emphasizes its unique business model based on specialization in R&D and manufacturing, and its dedication to ethical and safe production processes. The report outlines the company's strategies for solidifying its profit foundation and achieving sustained growth, including accelerating new drug discovery, expanding its global market reach, and implementing productivity improvements. The report also emphasizes the importance of corporate governance, compliance, and risk management, outlining the company's commitment to transparency, accountability, and ethical conduct. It further highlights the company's social contribution activities, focusing on its commitment to environmental sustainability, supporting the advancement of glycoscience, and fostering healthy communities. Overall, the report provides a comprehensive overview of Seikagaku Corporation's activities and its commitment to innovation, excellence, and social responsibility.
Go back to company
Seikagaku Corporation 2021 Corporate Report
Issuing Company Seikagaku Corporation
Report Type Integrated Report
Report Language EN
Report Filesize 2.92 MB
No. of Pages 28 pages
Reporting periodApril 1, 2020-March 31, 2021
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards Unknown
Materiality Assessmenttrue